Brookfield Capital Partners completed the acquisition of Antylia Scientific from GTCR for $1.4bn.

Brookfield Capital Partners, a global investment firm, completed the acquisition of Antylia Scientific, a provider of biopharma, environmental and life sciences, from GTCR, a private equity firm, for $1.4bn. "We are extraordinarily proud of the business transformation that Bernd, Jon and the entire Antylia team have been able to achieve over the last decade. From just an idea in 2014, to creating the current business through organic investment and M&A, we believe this is another great example of our Leaders Strategy™ approach, and we want to thank the entire Antylia team for their partnership," Sean Cunningham, GTCR Managing Director and Head of Healthcare.